Ilaria Vigliotta

Dr. Ilaria Vigliotta

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Cells
Verified
Journal Article
Open access
PDF file
EBEnrica Borsi
Enrica Borsi
IVIlaria Vigliotta
Ilaria Vigliotta
Andrea PolettiAndrea Poletti
Andrea Poletti
GMGaia Mazzocchetti
Gaia Mazzocchetti
VSVincenza Solli
Vincenza Solli
Carolina TerragnaCarolina Terragna
Carolina Terragna
Clonal hematopoiesis of indeterminate potential (CHIP) refers to the phenomenon where a hematopoietic stem cell acquires fitness-increasing mutation(s), resulting in its clonal expansion. CHIP is frequently observed in multiple myeloma (MM) patients, and it is associated with a worse outcome. High-throughput amplicon-based single-cell DNA sequencing was performed on circulating CD34+ cells collected from twelve MM patients before autologous stem cell transplantation (ASCT). Moreover, in four MM patients, longitudinal samples either before or post-ASCT were collected. Single-cell sequencing and data analysis were assessed using the MissionBio Tapestri® platform, with a targeted panel of 20 leukemia-associated genes. We detected CHIP pathogenic mutations in 6/12 patients (50%) at the time of transplant. The most frequently mutated genes were TET2, EZH2, KIT, DNMT3A, and ASXL1. In two patients, we observed co-occurring mutations involving an epigenetic modifier (i.e., DNMT3A) and/or a gene involved in splicing machinery (i.e., SF3B1) and/or a tyrosine kinase receptor (i.e., KIT) in the same clone. Longitudinal analysis of paired samples revealed a positive selection of mutant high-fitness clones over time, regardless of their affinity with a major or minor sub-clone. Copy number analysis of the panel of all genes did not show any numerical alterations present in stem cell compartment. Moreover, we observed a tendency of CHIP-positive patients to achieve a suboptimal response to therapy compared to those without. A sub-clone dynamic of high-fitness mutations over time was confirmed.

23 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IVIlaria Vigliotta
Ilaria Vigliotta
VSVincenza Solli
Vincenza Solli
SASilvia Armuzzi
Silvia Armuzzi
Marina MartelloMarina Martello
Marina Martello
Andrea PolettiAndrea Poletti
Andrea Poletti
Carolina TerragnaCarolina Terragna
Carolina Terragna
In recent years, liquid biopsy has emerged as a promising alternative to the bone marrow (BM) examination, since it is a minimally invasive technique allowing serial monitoring. Circulating multiple myeloma cells (CMMCs) enumerated using CELLSEARCH® were correlated with patients’ prognosis and measured under treatment to assess their role in monitoring disease dynamics. Forty-four MM and seven smouldering MM (SMM) patients were studied. The CMMC medians at diagnosis were 349 (1 to 39,940) and 327 (range 22–2463) for MM and SMM, respectively. In the MM patients, the CMMC count was correlated with serum albumin, calcium, β2-microglobulin, and monoclonal components (p < 0.04). Under therapy, the CMMCs were consistently detectable in 15/40 patients (coMMstant = 1) and were undetectable or decreasing in 25/40 patients (coMMstant = 0). High-quality response rates were lower in the coMMstant = 1 group (p = 0.04), with a 7.8-fold higher risk of death (p = 0.039), suggesting that continuous CMMC release is correlated with poor responses. In four MM patients, a single-cell DNA sequencing analysis on residual CMMCs confirmed the genomic pattern of the aberrations observed in the BM samples, also highlighting the presence of emerging clones. The CMMC kinetics during treatment were used to separate the patients into two subgroups based on the coMMstant index, with different responses and survival probabilities, providing evidence that CMMC persistence is associated with a poor disease course.

5 June 2022 in Hematological Oncology
Verified
Journal Article
Closed access
CSChiara Sartor
Chiara Sartor
MAMario Arpinati
Mario Arpinati
GCGabriella Chirumbolo
Gabriella Chirumbolo
LDLuca Dozza
Luca Dozza
GCGianluca Cristiano
Gianluca Cristiano
CPCristina Papayannidis
Cristina Papayannidis

Verified
Journal Article
Open access
PDF file
Marina MartelloMarina Martello
Marina Martello
VSVincenza Solli
Vincenza Solli
RTRosalinda Termini
Rosalinda Termini
AKAjsi Kanapari
Ajsi Kanapari
Daniel RemondiniDaniel Remondini
Daniel Remondini
Carolina TerragnaCarolina Terragna
Carolina Terragna
DNA microarrays and RNA-based sequencing approaches are considered important discovery tools in clinical medicine. However, cross-platform reproducibility studies undertaken so far have highlighted that microarrays are not able to accurately measure gene expression, particularly when they are expressed at low levels. Here, we consider the employment of a digital PCR assay (ddPCR) to validate a gene signature previously identified by gene expression profile. This signature included ten Hedgehog (HH) pathways’ genes able to stratify multiple myeloma (MM) patients according to their self-renewal status. Results show that the designed assay is able to validate gene expression data, both in a retrospective as well as in a prospective cohort. In addition, the plasma cells’ differentiation status determined by ddPCR was further confirmed by other techniques, such as flow cytometry, allowing the identification of patients with immature plasma cells’ phenotype (i.e., expressing CD19+/CD81+ markers) upregulating HH genes, as compared to others, whose plasma cells lose the expression of these markers and were more differentiated. To our knowledge, this is the first technical report of gene expression data validation by ddPCR instead of classical qPCR. This approach permitted the identification of a Maturation Index through the integration of molecular and phenotypic data, able to possibly define upfront the differentiation status of MM patients that would be clinically relevant in the future.

8 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IVIlaria Vigliotta
Ilaria Vigliotta
AVAlessia Varacalli
Alessia Varacalli
VSVincenza Solli
Vincenza Solli
BTBarbara Taurisano
Barbara Taurisano
SASilvia Armuzzi
Silvia Armuzzi
CTCarolina Terragna
Carolina Terragna
Multiple myeloma (MM) is characterized by the proliferation of malignant plasma cells (PCs) in the bone marrow (BM). The pathogenesis of MM is complex and multifactorial, with significant heterogeneity among patients, making risk stratification and disease monitoring difficult. In this study, the potential role of circulating plasma cells (CPCs), including polyclonal CPCs, as innovative biomarkers, was evaluated in 108 MM patients. Using next generation flow, CPCs in peripheral blood (PB) were analyzed, finding their presence in 92% of cases (monoclonal CPCs 77%, polyclonal CPCs 15%), with a median of 0.02% (range 0.002-9%). CPCs were significantly correlated with adverse clinical parameters and tumor burden (p < 0.05), indicating an association with a more aggressive phenotype even in the presence of polyclonal PCs. Notably, high CPCs-patients had mutations limited to KRAS, while patients with a low number of CPCs carried preferentially NRAS mutations. Lastly, comparisons between PCs phenotypes in BM and PB showed significant heterogeneity, such as variations in the expression of markers like CD56 and CD138, suggesting the potential migratory predisposition. Overall, the presence of both monoclonal and polyclonal CPCs, together with evidence of immunophenotypic and molecular heterogeneity, suggests that CPCs may reflect clinically relevant aspects of tumor dissemination and disease evolution.

7 November 2025 in Research Square
Verified
Preprint
Open access
PDF file
IVIlaria Vigliotta
Ilaria Vigliotta
AVAlessia Varacalli
Alessia Varacalli
VSVincenza Solli
Vincenza Solli
BTBarbara Taurisano
Barbara Taurisano
SASilvia Armuzzi
Silvia Armuzzi
CTCarolina Terragna
Carolina Terragna
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells (PCs) in the bone marrow (BM). The pathogenesis of MM is complex and multifactorial, with significant heterogeneity among patients, making risk stratification and disease monitoring difficult, often based on invasive sampling. Therefore, there is growing interest in less invasive methods such as liquid biopsy. In this study, the potential of circulating plasma cells (CPCs), including polyclonal CPCs, was evaluated as innovative biomarkers for risk stratification in 107 MM patients. Using multiparametric flow cytometry, the phenotypes of the CPCs in peripheral blood (PB) were analyzed, finding their presence in 92% of cases (monoclonal CPCs 77%, polyclonal CPCs 15%), with a median of 0.02% (range 0.002-9%). CPCs were significantly correlated with various biochemical parameters and the percentage of BM-PCs (p<0.05), indicating an association with a more aggressive phenotype even in the presence of polyclonal PCs. Genomic analyses identified recurrent mutations in key genes ( KRAS and NRAS ), potentially involved in CPCs formation. Notably, high CPCs-patients had mutation restricted to KRAS , while patients with a low amount of CPCs carried solely NRAS mutations. Lastly, comparisons between PC phenotypes in BM and PB showed significant heterogeneity, such as light chain inversion or variations in the expression of markers like CD56 and CD138, suggesting the presence of clonal heterogeneity and potential migratory predisposition. Such differences might have prognostic and therapeutic implications, and might contribute to the emergence of CPCs.